| Budget Amount *help |
¥18,200,000 (Direct Cost: ¥14,000,000、Indirect Cost: ¥4,200,000)
Fiscal Year 2014: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
Fiscal Year 2012: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
|
|---|
| Outline of Final Research Achievements |
The addition of lentinan, anti-tumor polysaccharide isolated from the fruit body of shiitake, on radiation to subcutaneous tumor of LuM-1 increased the number of Gr-1(+)CD11b(+) MDSC in splenocytes, although it could not induce the augment of antitumor effects of irradiated tumor as well as non-irradiated lung metastasis. Transfection of PS-PLA1 to LuM-1 can induce PS expression of irradiated cells. The effect of PS-PLA1 on radiosensitivity is under investigation. On the other hand, in patients with rectal cancer who received neoadjuvant chemoradiotherapy (CRT), the response is significantly associated with preoperative number of CD4(+) helper T lymphocytes, as well as platelet number, soluble CD40-ligand (sCD40L). Altogether, our data suggest that the tumor response of rectal cancer against RT is at least partly dependent on host immune response. Combination of immunotherapy to conventional (chemo)radiotherapy is a new approach for the improvement of the treatment of rectal cancer.
|
